Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.37 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249320 | 0.89 | OGA (0.39) | MEN1KMT2AOGAPANK3TRPV1 | |
| SCHEMBL20249352 | 0.82 | TRPV1 (0.39) | OGATRPV1 | |
| SCHEMBL20255523 | 0.81 | DRD2 (0.46) | DRD2DRD3MEN1KMT2ASLC6A3 | |
| SCHEMBL20249351 | 0.80 | TRPV1 (0.38) | OGATRPV1RET | |
| SCHEMBL20249151 | 0.80 | GAA (0.47) | DRD2DRD3MEN1KMT2ATRPV1 | |
| SCHEMBL20038242 | 0.80 | OGA (0.46) | DRD2DRD3MEN1KMT2ASLC6A3 | |
| SCHEMBL20249301 | 0.80 | TRPV1 (0.36) | OGATRPV1 | |
| SCHEMBL20249325 | 0.78 | HRH3 (0.48) | OGAPANK3TRPV1 | |
| SCHEMBL20249304 | 0.78 | OGA (0.42) | OGAPANK3TRPV1 | |
| SCHEMBL20249395 | 0.77 | OGA (0.39) | DRD2DRD3OGAPANK3TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | DRD2 1592/4885DRD3 1769/4885MEN1 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.